Clinical Trial Update: Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating the safety and preliminary efficacy of bortezomib in combination with CC-5013 (lenalidomide) in patients with relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Status: COMPLETED